BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 10733517)

  • 1. Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease.
    Anderson LD; Savary CA; Mullen CA
    Blood; 2000 Apr; 95(7):2426-33. PubMed ID: 10733517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
    Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
    Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine.
    Anderson LD; Petropoulos D; Everse LA; Mullen CA
    Cancer Res; 1999 Apr; 59(7):1525-30. PubMed ID: 10197624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular tumor vaccines administered after T cell-depleted allogeneic bone marrow transplantation induce effective anti-tumor immune responses.
    Mundhada S; Shaw J; Mori S; Savary CA; Mullen CA
    Leuk Lymphoma; 2005 Apr; 46(4):571-80. PubMed ID: 16019486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
    Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
    J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of immunodominance among minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation.
    Mori S; El-Baki H; Mullen CA
    Bone Marrow Transplant; 2003 May; 31(10):865-75. PubMed ID: 12748663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation.
    Teshima T; Liu C; Lowler KP; Dranoff G; Ferrara JL
    Cancer Res; 2002 Feb; 62(3):796-800. PubMed ID: 11830535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solid Tumor-Induced Immune Regulation Alters the GvHD/GvT Paradigm after Allogenic Bone Marrow Transplantation.
    Dang N; Lin Y; Rutgeerts O; Sagaert X; Billiau AD; Waer M; Sprangers B
    Cancer Res; 2019 May; 79(10):2709-2721. PubMed ID: 30936086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow deficient in IFN-{gamma} signaling selectively reverses GVHD-associated immunosuppression and enhances a tumor-specific GVT effect.
    Capitini CM; Herby S; Milliron M; Anver MR; Mackall CL; Fry TJ
    Blood; 2009 May; 113(20):5002-9. PubMed ID: 19258593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donor T cells lacking Fas ligand and perforin retain the capacity to induce severe GvHD in minor histocompatibility antigen mismatched bone-marrow transplantation recipients.
    Marks L; Altman NH; Podack ER; Levy RB
    Transplantation; 2004 Mar; 77(6):804-12. PubMed ID: 15077018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation.
    Teshima T; Mach N; Hill GR; Pan L; Gillessen S; Dranoff G; Ferrara JL
    Cancer Res; 2001 Jan; 61(1):162-71. PubMed ID: 11196155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation.
    Kohrt HE; Müller A; Baker J; Goldstein MJ; Newell E; Dutt S; Czerwinski D; Lowsky R; Strober S
    Blood; 2011 Nov; 118(19):5319-29. PubMed ID: 21868578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of tumor vaccines on graft versus tumor activity and graft versus host disease in allogeneic bone marrow transplantation.
    Mullen CA
    Leuk Lymphoma; 2002 Mar; 43(3):503-10. PubMed ID: 12002752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fas-deficient lpr mice are more susceptible to graft-versus-host disease.
    van Den Brink MR; Moore E; Horndasch KJ; Crawford JM; Hoffman J; Murphy GF; Burakoff SJ
    J Immunol; 2000 Jan; 164(1):469-80. PubMed ID: 10605044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic bone marrow transplantation for hepatocellular carcinoma: hepatocyte growth factor suppresses graft-vs.-host disease.
    Yoshida Y; Hirano T; Son G; Iimuro Y; Imado T; Iwasaki T; Fujimoto J
    Am J Physiol Gastrointest Liver Physiol; 2007 Dec; 293(6):G1114-23. PubMed ID: 17761834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease.
    Pan L; Teshima T; Hill GR; Bungard D; Brinson YS; Reddy VS; Cooke KR; Ferrara JL
    Blood; 1999 Jun; 93(12):4071-8. PubMed ID: 10361103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irradiated donor leukocytes promote engraftment of allogeneic bone marrow in major histocompatibility complex mismatched recipients without causing graft-versus-host disease.
    Waller EK; Ship AM; Mittelstaedt S; Murray TW; Carter R; Kakhniashvili I; Lonial S; Holden JT; Boyer MW
    Blood; 1999 Nov; 94(9):3222-33. PubMed ID: 10556211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergism of interleukin-2 and cyclosporine A in induction of a graft-versus-tumor effect without graft-versus-host disease after syngeneic bone marrow transplantation.
    Charak BS; Agah R; Mazumder A
    Blood; 1992 Jul; 80(1):179-84. PubMed ID: 1611084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.
    Lu SX; Kappel LW; Charbonneau-Allard AM; Atallah R; Holland AM; Turbide C; Hubbard VM; Rotolo JA; Smith M; Suh D; King C; Rao UK; Yim N; Bautista JL; Jenq RR; Penack O; Na IK; Liu C; Murphy G; Alpdogan O; Blumberg RS; Macian F; Holmes KV; Beauchemin N; van den Brink MR
    PLoS One; 2011; 6(7):e21611. PubMed ID: 21760897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.